When Curing a Disease with Gene Therapy Is Bad Business
April 16, 2018
(MIT Technology Review) – Just today, we saw GlaxoSmithKline sell off its pipeline of gene therapies for rare disease to a London startup called Orchard Therapeutics for a 20 percent stake in the young company. The treatments Glaxo didn’t want were bona fide miracles: one-and-done cures that replace a broken gene and save a life. One was Strimvelis, a therapy for a rare immune deficiency that’s been curing kids outright.